Background Image
Previous Page  134 / 156 Next Page
Information
Show Menu
Previous Page 134 / 156 Next Page
Page Background

132

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

100

Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough

pain in patients compared to immediate release morphine sulfate tablet. Pain Pract 2007;

7(4): 324-331.

101

Freye E. Opioide in der Medizin. Springer Verlag Heidelberg, 8. Auflage, 2010;

102

Gamal G, Helaly M, Labib YM. Superior hypogastric block: transdiscal versus classic poste-

rior approach in pelvic cancer pain. Clin J Pain 2006; 22(6): 544-547.

103

García de Paredes ML, del Moral González F, Martínez del Prado P, Martí Ciriquián JL, En-

rech Francés S, Cobo Dols M, Esteban González E, Ortega Granados AL, Majem Tarruella

M, Cumplido Burón JD, Gascó Hernández A, López Miranda E, Ciria Santos JP, de Castro

Carpeño FJ. First evidence of oncologic neuropathic pain prevalence after screening 8615

cancer patients. Results of the On study. Ann Oncol 2011; 22(4): 924-930.

104

Gartner R, Kroman N, Callesen T, Kehlet H. Multimodal prevention of pain, nausea and

vomiting after breast cancer surgery. Minerva Anestesiol 2010; 76(10): 805-813.

105

Gatti A, Longo G, Sabato E, Sabato AF. Long-term controlled-release oxycodone and

pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol 2011;

65(6): 317-322.

106

Gatti A, Reale C, Luzi M, Canneti A, Mediati RD, Vellucci R, Mammucari M, Sabato AF.

Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig

2010; 30 Suppl 2: 39-47.

107

Gatti A, Reale C, Occhioni R, Luzi M, Canneti A, De Polo C, Gubernari M, Mammucari M,

Fabrizio Sabato A. Standard therapy with opioids in chronic pain management : ORTIBER

study. Clin Drug Investig 2009; 29 Suppl 1: 17-23.

108

Gazoni FM, Pouratian N, Nemergut EC. Effect of ropivacaine skull block on perioperative

outcomes in patients with supratentorial brain tumors and comparison with remifentanil:

a pilot study. J Neurosurg 2008; 109(1): 44-49.

109

GEISSLINGER, G. Opioide differenziert einsetzen, STK-Zeitschrift für angewandte

Schmerztherapie 3/99; 4-6. 2/00; 7-9.

110

Good P, Jackson K, Brumley D, Ashby M. Intranasal sufentanil for cancer-associated

breakthrough pain. Palliat Med 2009; 23(1): 54-58.

111

Goodchild CS, Nelson J, Cooke I, Ashby M, Jackson K. Combination therapy with flupirtine

and opioid: open-label case series in the treatment of neuropathic pain associated with

cancer. Pain Med 2008; 9(7): 939-949.

112

Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates (Re-

view). Journal of Pain and Symptom Management 2007; 33 (4), 462-472.

113

Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G. Epidemiology and

pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients:

results from the Cancer Pain Outcome Research Study Group. Clin J Pain 2011; 27(1):

9-18.

114

Greco MT, Deandrea S, Corli O, Montanari M, Caraceni A, Apolone G. [Effects of transder-

mal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research

(CPOR) Study Group]. Recenti Prog Med 2008; 99(11): 538-551.

Literaturverzeichnis